Module 15: Clinical Pharmacology Guide for Patient Treatment

Expanded update focused on: which named drugs are used for which diseases, likely route, first-line choices, alternatives, monitoring, contraindications/cautions, and clinical pearls. Built only from your uploaded pharmacology/pathophysiology/course resources and transformed into a patient-treatment study format. Verify current guidelines, local antibiograms, dose adjustments, pregnancy status, renal/hepatic function, and product labeling before real clinical use.

Ready

Foundations: Treatment Logic, PK/PD, Receptors, Safety Cardiovascular System Pulmonary / ENT / Respiratory Infections Endocrine / Metabolic Renal / Urologic / Fluid-Electrolyte

Quick Drug Picks: Disease -> First-Line Named Drug(s) and Route

Disease / condition	First-line or common initial option from course/app sources	Escalation / note
Nonpurulent cellulitis	cephalexin PO or dicloxacillin PO; severe: cefazolin IV or ceftriaxone IV	Add vancomycin IV if MRSA/systemic risk
Purulent SSTI/MRSA risk	I&D if abscess; doxycycline PO or TMP-SMX PO for outpatient MRSA coverage	Severe/systemic: vancomycin IV
CAP outpatient	amoxicillin PO or doxycycline PO	Hospital/severe: ceftriaxone IV + azithromycin IV/PO or protocol regimen
Strep pharyngitis	penicillin V PO or amoxicillin PO	benzathine penicillin G IM if adherence concern
Acute otitis media	amoxicillin PO	amoxicillin-clavulanate PO when indicated
Meningitis	vancomycin IV + ceftriaxone IV	add ampicillin IV for Listeria-risk patients
UTI cystitis	nitrofurantoin PO, TMP-SMX PO, fosfomycin PO	culture-guided alternatives
Pyelonephritis	ciprofloxacin/levofloxacin PO if stable/susceptible; ceftriaxone IV if severe/initial	hospital IV therapy if vomiting/sepsis/pregnancy
Chlamydia	doxycycline PO	azithromycin PO alternative in selected situations
Gonorrhea	ceftriaxone IM	verify current protocol and treat chlamydia if not excluded
Trichomoniasis/BV	metronidazole PO	partner treatment for trichomoniasis
H. pylori	PPI + amoxicillin + clarithromycin when appropriate	bismuth quadruple therapy per protocol
C. difficile	oral vancomycin	metronidazole listed in course; verify severity/current protocol
Asthma acute relief	albuterol inhaled/nebulized	systemic prednisone for significant exacerbation
COPD maintenance	tiotropium inhaled, salmeterol/formoterol, albuterol PRN	ICS/LABA or triple therapy if exacerbation-prone
Hypertension	chlorthalidone/HCTZ, lisinopril/enalapril, losartan/valsartan, amlodipine	combine first-line classes if not controlled
HFrEF	sacubitril/valsartan or ACEI/ARB, metoprolol succinate/carvedilol/bisoprolol, spironolactone, furosemide	SGLT2 inhibitor per protocol
AF rate	metoprolol, diltiazem, verapamil	digoxin selected patients
VTE	apixaban/rivaroxaban or heparin/LMWH to warfarin	massive PE thrombolysis per emergency protocol
Depression	SSRI such as sertraline/escitalopram/fluoxetine or SNRI duloxetine/venlafaxine	bupropion/mirtazapine/TCA later-line
ADHD	methylphenidate or amphetamine	atomoxetine second-line; guanfacine/clonidine; bupropion third-line
Gout flare	NSAID, colchicine, or prednisone	choose based on renal/GI/CV risk
Osteoarthritis	topical diclofenac, acetaminophen, oral NSAID if safe	intra-articular steroid selected patients

Route principle: PO is used for stable outpatient infections when absorption is reliable; IV is used for sepsis, meningitis, severe pneumonia, severe SSTI, inability to take PO, severe immunocompromise, or need for rapidly reliable levels.

Foundations: Treatment Logic, PK/PD, Receptors, Safety

Clinical prescribing workflow

Pathophysiology: Define the diagnosis and disease severity; identify patient-specific risks (age, pregnancy/lactation, renal/hepatic function, allergies, genetics, adherence, cost); choose the narrowest effective regimen; educate; monitor response and toxicity.

First-line / initial treatment: Use the 8-step prescribing approach from your course: evaluate problem, set therapeutic objective, select drug, initiate with details/non-drug therapy, give instructions/warnings, evaluate, consider cost, and use tools to reduce errors.

Alternatives / escalation: When uncertain, confirm diagnosis before escalating therapy; culture/diagnostics when results change treatment.

Monitoring / contraindications: Therapeutic target, adverse effects, labs, adherence, drug interactions, and stop dates for time-limited therapy.

Clinical pearl: A treatment table is not a substitute for current product labeling or local protocols; renal dose adjustment and pregnancy safety must be checked every time.

Pharmacokinetics: ADME

Pathophysiology: Absorption, distribution, metabolism, and elimination determine onset, intensity, duration, and toxicity. IV avoids absorption and first-pass metabolism; oral therapy depends on GI conditions and hepatic first-pass; lipid solubility and protein binding affect distribution; CYP metabolism and renal excretion influence interactions and dosing.

First-line / initial treatment: Select route by urgency and site: IV for emergencies/poor oral absorption; PO for stable outpatient therapy; topical/inhaled for local effect; transdermal for sustained systemic delivery.

Alternatives / escalation: Switch IV-to-PO when clinically improving, able to absorb, and an oral equivalent exists.

Monitoring / contraindications: Renal function, hepatic function, albumin, drug levels when narrow therapeutic index, and response time based on half-life/steady state.

Clinical pearl: Low albumin increases free highly protein-bound drugs; kidney disease raises toxicity risk for renally cleared drugs such as aminoglycosides, vancomycin, lithium, digoxin, metformin, and many antibiotics.

Pharmacodynamics and receptors

Pathophysiology: Drug response depends on receptors, enzymes, ion channels, transporters, and immune targets. Agonists activate receptors; antagonists block receptors; inhibitors reduce enzyme or transporter activity.

First-line / initial treatment: Match mechanism to pathophysiology: 2 agonists for bronchospasm, ACEI/ARB for RAAS-driven BP/renal protection, statins for hepatic cholesterol synthesis, PPIs for gastric acid suppression, SSRIs/SNRIs for monoamine reuptake inhibition.

Alternatives / escalation: If inadequate response, optimize dose/adherence first, then switch class or add synergistic mechanism when supported by course materials.

Monitoring / contraindications: Efficacy marker tied to mechanism: BP, heart rate, A1c, LDL, INR, symptom scores, exacerbation frequency, cultures, or pain/function.

Clinical pearl: The same receptor can be therapeutic in one tissue and toxic in another; selectivity and dose matter.

Toxicology and antidotes

Pathophysiology: Toxicity may be predictable pharmacologic excess (Type A) or idiosyncratic/unrelated to primary action (Type B). Initial care is stabilization plus toxidrome recognition.

First-line / initial treatment: Stabilize airway, breathing, circulation, glucose, mental status, and temperature; identify drug/time/dose/route/co-ingestants; use antidotes when indicated.

Alternatives / escalation: Activated charcoal may be appropriate for selected recent ingestions when airway is protected; dialysis is used for selected dialyzable toxins.

Monitoring / contraindications: Vitals, ECG/QT/QRS, glucose, electrolytes, renal/liver tests, drug levels when available, acetaminophen level/time nomogram.

Clinical pearl: Named antidotes: naloxone-opioids; N-acetylcysteine-acetaminophen; atropine + pralidoxime-organophosphates; vitamin K/PCC-warfarin; protamine-heparin; glucagon-beta-blocker toxicity; benzodiazepines-seizures/agitation from many toxidromes.

Cardiovascular System

Hypertension, uncomplicated

Pathophysiology: Sustained elevated BP increases vascular resistance and causes target-organ injury: LVH, CKD, stroke, CAD, retinopathy. RAAS activation, sympathetic tone, sodium/water retention, vascular remodeling, obesity, sleep apnea, CKD, and drugs can contribute.

First-line / initial treatment: Lifestyle for all. First-line drug options: thiazide/thiazide-like diuretic (chlorthalidone, hydrochlorothiazide), ACE inhibitor (lisinopril, enalapril), ARB (losartan, valsartan), or calcium-channel blocker (amlodipine, nifedipine). Diabetes/CKD/proteinuria: ACEI or ARB often preferred when tolerated. Black adults without HF/CKD: thiazide or CCB is emphasized in guideline materials.

Alternatives / escalation: If not controlled: titrate to max tolerated dose or add another first-line class. Resistant HTN: consider spironolactone/eplerenone after assessing K/renal function and secondary causes.

Monitoring / contraindications: BP log, orthostasis, K/Na, creatinine/eGFR, edema, cough/angioedema with ACEI, adherence, NSAID/decongestant use.

Clinical pearl: ACEI + ARB combination is generally avoided because of renal impairment, hypotension, and hyperkalemia risk.

Hypertensive urgency vs emergency

Pathophysiology: Urgency is severe BP elevation without acute target-organ injury; emergency includes acute organ injury such as encephalopathy, MI, pulmonary edema, aortic dissection, stroke/ICH, AKI, or eclampsia.

First-line / initial treatment: Emergency: hospital/ICU, IV therapy such as nicardipine IV, clevidipine IV, labetalol IV, nitroglycerin IV, nitroprusside IV, hydralazine IV, or enalaprilat IV depending on comorbidity. Urgency: reinstitute/intensify oral therapy and close follow-up rather than rapid IV lowering.

Alternatives / escalation: Aortic dissection: -blockade first (esmolol/labetalol) plus vasodilator if needed. Pulmonary edema: nitroglycerin/loop diuretic strategies. Pregnancy/eclampsia: labetalol/hydralazine/nifedipine per obstetric protocol.

Monitoring / contraindications: Continuous BP, neurologic status, chest pain, renal output, ECG, troponin, creatinine, electrolytes.

Clinical pearl: Do not treat severe asymptomatic BP like an emergency; the presence of acute organ damage drives the route and urgency.

Hyperlipidemia / ASCVD prevention

Pathophysiology: LDL-C and apoB-containing particles drive atherosclerotic plaque formation. Plaque rupture causes MI/stroke; diabetes, CKD, smoking, HTN, and inflammation increase risk.

First-line / initial treatment: Clinical ASCVD or LDL >=190 mg/dL: high-intensity statin when tolerated-atorvastatin 40-80 mg PO daily or rosuvastatin 20-40 mg PO daily. Diabetes age 40-75 or intermediate risk: moderate-intensity statin-atorvastatin 10-20 mg, rosuvastatin 5-10 mg, simvastatin 20-40 mg, pravastatin 40-80 mg.

Alternatives / escalation: If LDL remains above target/threshold on maximally tolerated statin: add ezetimibe PO; very high-risk patients may need PCSK9 inhibitor alirocumab/evolocumab SQ. Severe hypertriglyceridemia: fenofibrate or gemfibrozil; omega-3 products in selected patients.

Monitoring / contraindications: Baseline risk, fasting lipids 4-12 weeks after start/change then periodically, muscle symptoms, drug interactions, pregnancy status, LFT symptoms.

Clinical pearl: Macrolides/azole antifungals can increase statin toxicity risk. Muscle pain + CK elevation or rhabdomyolysis symptoms requires urgent reassessment.

Stable angina / coronary artery disease

Pathophysiology: Myocardial oxygen demand exceeds supply because of coronary atherosclerosis or spasm. Ischemia causes chest pressure, dyspnea, diaphoresis, nausea, or atypical symptoms.

First-line / initial treatment: Symptom relief: nitroglycerin SL PRN. Prevention: aspirin when appropriate, high-intensity statin, -blocker such as metoprolol for angina/post-MI, ACEI/ARB if HTN/diabetes/CKD/HFrEF, smoking cessation and risk reduction.

Alternatives / escalation: If -blocker not tolerated or vasospasm suspected: CCB such as amlodipine, diltiazem, or verapamil; long-acting nitrates or ranolazine for persistent symptoms.

Monitoring / contraindications: Chest pain pattern, exercise tolerance, BP/HR, nitrate hypotension, PDE-5 inhibitor use, ECG/stress testing as indicated.

Clinical pearl: New, worsening, or rest chest pain is not stable angina-evaluate for ACS.

Acute coronary syndrome / STEMI / post-MI

Pathophysiology: Plaque rupture and thrombosis obstruct coronary blood flow. Prolonged ischemia causes myocardial necrosis with troponin elevation and ECG changes.

First-line / initial treatment: Emergency reperfusion for STEMI per protocol. Adjuncts commonly include aspirin, P2Y12 inhibitor (clopidogrel/ticagrelor/prasugrel per protocol), anticoagulation (heparin), high-intensity statin, -blocker if no contraindication, ACEI/ARB after stabilization, nitroglycerin/morphine selectively.

Alternatives / escalation: Fibrinolysis when PCI unavailable within appropriate time window and no contraindications; secondary prevention with statin, antiplatelet therapy, -blocker, ACEI/ARB, aldosterone antagonist in selected HFrEF/diabetes.

Monitoring / contraindications: ECG, troponin, BP/HR, bleeding, renal function, potassium, EF, recurrent ischemia.

Clinical pearl: Do not delay emergency care for textbook confirmation; ACS is a protocol-driven emergency.

Heart failure with reduced EF (HFrEF)

Pathophysiology: Reduced contractility triggers sympathetic and RAAS activation, sodium/water retention, remodeling, pulmonary/systemic congestion, and reduced perfusion.

First-line / initial treatment: Core medication groups: ACEI/ARB or ARNI (sacubitril/valsartan where appropriate), evidence -blocker (metoprolol succinate, carvedilol, bisoprolol), mineralocorticoid receptor antagonist (spironolactone/eplerenone), loop diuretic (furosemide/torsemide/bumetanide) for congestion, SGLT2 inhibitor (empagliflozin/dapagliflozin) if included in current practice protocol.

Alternatives / escalation: Hydralazine + isosorbide dinitrate when ACEI/ARB/ARNI not tolerated or in selected patients; digoxin for symptoms/rate; ivabradine in selected sinus rhythm tachycardia.

Monitoring / contraindications: Weight, edema, dyspnea, BP/HR, K, creatinine, volume status, adherence, NSAID avoidance.

Clinical pearl: Diuretics improve congestion but do not replace mortality-benefit neurohormonal therapy.

Atrial fibrillation

Pathophysiology: Disorganized atrial electrical activity causes irregularly irregular rhythm and atrial stasis, increasing embolic stroke risk.

First-line / initial treatment: Rate control: metoprolol, diltiazem, or verapamil when appropriate; digoxin in selected patients. Stroke prevention: warfarin or DOAC (apixaban, rivaroxaban, dabigatran, edoxaban) based on risk and renal/valve status.

Alternatives / escalation: Rhythm control: amiodarone, sotalol, flecainide/propafenone in selected patients; cardioversion/ablation per specialist/protocol.

Monitoring / contraindications: ECG, HR, symptoms, anticoagulant bleeding, renal function for DOACs, INR for warfarin, thyroid/liver/lung toxicity with amiodarone.

Clinical pearl: Mechanical valves and some valvular situations require warfarin rather than DOACs.

Arrhythmias: SVT, ventricular arrhythmia, bradycardia

Pathophysiology: Abnormal impulse formation or conduction creates tachyarrhythmia or bradyarrhythmia, causing palpitations, syncope, hypotension, or sudden death risk.

First-line / initial treatment: SVT: vagal maneuvers then adenosine IV per protocol. Ventricular arrhythmia: amiodarone or lidocaine per ACLS/specialist protocol. Symptomatic bradycardia: atropine IV then pacing/chronotrope per protocol.

Alternatives / escalation: Long-term options depend on rhythm: -blockers, CCBs, antiarrhythmics, ablation, pacemaker/ICD.

Monitoring / contraindications: ECG/QT, electrolytes Mg/K, renal/hepatic function, drug interactions, hemodynamic stability.

Clinical pearl: Correct hypokalemia/hypomagnesemia and remove offending QT-prolonging drugs when possible.

Peripheral edema / volume overload

Pathophysiology: Edema results from increased hydrostatic pressure, reduced oncotic pressure, sodium retention, lymphatic obstruction, or inflammation. HF, CKD, cirrhosis, nephrotic syndrome, venous disease, and CCBs are common causes.

First-line / initial treatment: Treat cause. HF/CKD fluid overload: loop diuretic furosemide/torsemide/bumetanide; sodium restriction as appropriate. Venous edema: compression/elevation if no arterial contraindication.

Alternatives / escalation: Thiazide-like add-on for diuretic resistance under monitoring; spironolactone for cirrhosis/aldosterone-mediated states per protocol.

Monitoring / contraindications: Weight, urine output, edema, BP, Na/K/Mg, creatinine, orthostasis.

Clinical pearl: Amlodipine edema often does not respond well to diuretics; consider dose reduction/switch if clinically appropriate.

Pulmonary / ENT / Respiratory Infections

Common cold / viral URI / acute infectious rhinitis

Pathophysiology: Usually viral; rhinovirus is emphasized as most common in course material. Symptoms include clear rhinorrhea, congestion, sneezing, sore throat, cough, low-grade fever, malaise.

First-line / initial treatment: Supportive care: fluids, rest, saline, acetaminophen/ibuprofen if appropriate. Symptom drugs: pseudoephedrine PO or oxymetazoline nasal short term for congestion; guaifenesin for mucus; dextromethorphan or benzonatate for cough; ipratropium nasal for rhinorrhea in selected patients.

Alternatives / escalation: Avoid antibiotics unless bacterial diagnosis is supported. Influenza antivirals only when influenza suspected/confirmed and timing/risk fits protocol.

Monitoring / contraindications: Fever duration, dyspnea, hypoxia, worsening after initial improvement, high-risk patients.

Clinical pearl: Most acute bronchitis/URI cases are viral; antibiotic stewardship is part of treatment.

Asthma

Pathophysiology: Chronic airway inflammation with bronchial hyperresponsiveness and reversible obstruction. Triggers cause bronchoconstriction, mucus, edema, wheeze, cough, chest tightness.

First-line / initial treatment: Reliever/controller approach per asthma severity. Common drugs: albuterol inhaler/nebulizer for acute bronchospasm; inhaled corticosteroid such as budesonide/fluticasone as anti-inflammatory controller; ICS-formoterol regimens where used by guideline/protocol; oral prednisone for significant exacerbations.

Alternatives / escalation: Add LABA (formoterol/salmeterol) only with ICS, leukotriene receptor antagonist montelukast, LAMA tiotropium, biologics such as omalizumab/mepolizumab for selected severe phenotypes.

Monitoring / contraindications: Symptoms, nighttime awakening, rescue use, exacerbations, peak flow/spirometry, inhaler technique, oral thrush, steroid effects.

Clinical pearl: LABA monotherapy is avoided in asthma; inhaler technique can mimic treatment failure.

COPD / chronic bronchitis / emphysema

Pathophysiology: Chronic airflow limitation due to airway inflammation, mucus hypersecretion, and alveolar destruction. Smoking is a major driver. Exacerbations worsen dyspnea, sputum, cough.

First-line / initial treatment: Smoking cessation. Bronchodilators: SABA albuterol PRN, SAMA ipratropium, LAMA tiotropium, LABA salmeterol/formoterol. Exacerbation: short-acting bronchodilators, systemic corticosteroid such as prednisone, antibiotics when bacterial features/severity present, oxygen with appropriate targets.

Alternatives / escalation: ICS/LABA or triple therapy for selected exacerbation-prone patients; roflumilast for chronic bronchitis phenotype; pulmonary rehab, vaccines.

Monitoring / contraindications: Dyspnea, exacerbations, O2 saturation, spirometry, pneumonia risk with ICS, anticholinergic urinary/glaucoma cautions.

Clinical pearl: Bronchodilators are the cornerstone; ICS is not automatically first-line for every COPD patient.

Community-acquired pneumonia (CAP)

Pathophysiology: Infection of alveoli/interstitium causes inflammation, consolidation, fever, cough, sputum, pleuritic pain, dyspnea, hypoxia. Typical and atypical pathogens influence antibiotic choice.

First-line / initial treatment: Course materials list amoxicillin or doxycycline as common outpatient choices for CAP/acute cough contexts. Stable outpatient: amoxicillin PO or doxycycline PO when appropriate. Comorbid/severe/hospital: broader regimens such as -lactam plus macrolide or respiratory fluoroquinolone per protocol.

Alternatives / escalation: Macrolides (azithromycin) when atypical coverage needed and resistance/local protocol allows; ceftriaxone IV + azithromycin IV/PO for hospitalized non-ICU patterns in many protocols.

Monitoring / contraindications: Vitals, oxygenation, fever curve, WBC, renal function, QT risk, C. difficile risk, clinical improvement in 48-72h.

Clinical pearl: Route depends on severity: PO for stable outpatient; IV for severe disease, inability to take PO, hypoxia, sepsis, or hospitalization.

Acute bacterial sinusitis / strep pharyngitis / otitis media

Pathophysiology: Bacterial upper respiratory infection is suggested by persistent, severe, or worsening symptoms rather than early viral symptoms alone. Strep pharyngitis is group A streptococcal infection; AOM is middle-ear infection.

First-line / initial treatment: Sinusitis/AOM: amoxicillin PO often first-line in course materials; amoxicillin-clavulanate PO for selected resistant/severe/recent antibiotic cases. Strep throat: penicillin V PO or amoxicillin PO; benzathine penicillin G IM when adherence is a concern.

Alternatives / escalation: Cephalexin for non-anaphylactic penicillin allergy; azithromycin/clindamycin in selected allergy situations per protocol/local resistance.

Monitoring / contraindications: Fever, pain, complications, allergy, diarrhea, adherence.

Clinical pearl: Do not use antibiotics for uncomplicated early viral URI.

Pulmonary embolism

Pathophysiology: Venous clot embolizes to pulmonary arteries, causing V/Q mismatch, hypoxemia, strain on right ventricle. Virchow triad: stasis, endothelial injury, hypercoagulability.

First-line / initial treatment: Anticoagulation when PE confirmed or highly suspected and bleeding risk acceptable: heparin IV/LMWH initially; DOACs such as apixaban/rivaroxaban for many stable patients; warfarin with bridge in selected patients.

Alternatives / escalation: Thrombolysis/embolectomy for massive PE with shock per emergency protocol.

Monitoring / contraindications: O2, BP, RV strain, bleeding, renal function, drug interactions, duration indication.

Clinical pearl: Sudden dyspnea, pleuritic pain, tachycardia, syncope, hypoxia after risk factors requires urgent evaluation.

Croup, epiglottitis, neonatal RDS (pathophysiology bridge)

Pathophysiology: Croup: viral laryngotracheobronchitis causing upper airway edema and stridor. Epiglottitis: rapidly progressive epiglottic infection with airway risk. Neonatal RDS: surfactant deficiency in preterm infants causing atelectasis and distress.

First-line / initial treatment: Croup: dexamethasone and nebulized epinephrine for moderate/severe per protocol. Epiglottitis: airway protection, IV antibiotics such as ceftriaxone/cefotaxime plus airway team. RDS newborn: surfactant and ventilatory support in neonatal care.

Alternatives / escalation: Supportive oxygen/hydration; avoid agitating suspected epiglottitis patient.

Monitoring / contraindications: Work of breathing, stridor, oxygenation, fatigue, airway obstruction.

Clinical pearl: Epiglottitis is an airway emergency, not a routine sore throat.

Endocrine / Metabolic

Type 1 diabetes mellitus

Pathophysiology: Autoimmune beta-cell destruction causes absolute insulin deficiency, hyperglycemia, ketosis risk, weight loss, polyuria, polydipsia.

First-line / initial treatment: Insulin is required: basal insulin glargine/detemir/degludec plus rapid-acting mealtime insulin lispro/aspart/glulisine; regular insulin/NPH may be used in some regimens.

Alternatives / escalation: Pump therapy/CGM; carbohydrate counting and correction factor; glucagon for severe hypoglycemia rescue.

Monitoring / contraindications: A1c, SMBG/CGM, hypoglycemia, renal function, lipids, BP, eye/foot/urine albumin screening, injection sites.

Clinical pearl: Do not stop basal insulin in type 1 DM; illness increases DKA risk.

Type 2 diabetes mellitus

Pathophysiology: Insulin resistance plus progressive beta-cell dysfunction causes hyperglycemia; often associated with obesity, HTN, dyslipidemia, fatty liver, CKD/CVD risk.

First-line / initial treatment: Lifestyle plus metformin PO if tolerated and renal function appropriate. Add based on comorbidities: GLP-1 RA (semaglutide/liraglutide) for weight/CV benefit; SGLT2 inhibitor (empagliflozin/canagliflozin/dapagliflozin) for CKD/HF/CV benefit; insulin when symptomatic severe hyperglycemia or uncontrolled.

Alternatives / escalation: Sulfonylureas glipizide/glyburide, DPP-4 inhibitors sitagliptin, TZD pioglitazone, basal insulin glargine/NPH, prandial insulin.

Monitoring / contraindications: A1c, glucose, weight, renal function, hypoglycemia, GI intolerance, genital infections, edema/HF risk with TZD.

Clinical pearl: Course insulin calculation: estimate TDD by weight, then split basal/bolus when using basal-bolus regimens; individualize and monitor closely.

Prediabetes / metabolic syndrome / obesity

Pathophysiology: Insulin resistance and adiposity increase cardiometabolic risk. Obesity pathophysiology involves energy balance, appetite regulation, adipokines, inflammation, and comorbidity clustering.

First-line / initial treatment: Nutrition, activity, sleep, behavioral interventions, weight goal setting. Metformin for selected high-risk prediabetes. Anti-obesity drugs in selected patients: orlistat, GLP-1 RA class where appropriate; bariatric referral when criteria met.

Alternatives / escalation: Treat comorbid HTN/lipids/OSA; avoid weight-promoting drugs when alternatives exist.

Monitoring / contraindications: Weight, waist, BP, A1c, lipids, medication GI effects, nutritional deficiencies after surgery.

Clinical pearl: Weight loss improves BP, glycemic control, lipids, OA symptoms, and fatty liver risk.

DKA / HHS / severe hypoglycemia

Pathophysiology: DKA: insulin deficiency -> lipolysis/ketones, anion gap acidosis, dehydration. HHS: severe hyperglycemia/hyperosmolarity with minimal ketosis. Hypoglycemia: excess insulin/secretagogue, missed meals, renal decline, alcohol, exercise.

First-line / initial treatment: DKA/HHS: emergency protocol with IV fluids, IV regular insulin, potassium/electrolyte management, trigger treatment. Severe hypoglycemia: oral glucose if alert; glucagon IM/SC/intranasal or IV dextrose if unable to swallow/altered.

Alternatives / escalation: Transition to basal insulin before stopping IV insulin per protocol.

Monitoring / contraindications: Glucose hourly, K, anion gap/bicarb, osmolality, mental status, urine output, precipitating infection/MI.

Clinical pearl: Potassium must be assessed before insulin infusion because insulin shifts K intracellularly.

Hypothyroidism / myxedema coma

Pathophysiology: Low thyroid hormone slows metabolism, causing fatigue, cold intolerance, constipation, bradycardia, weight gain; severe decompensation can cause hypothermia, altered mental status, hypoventilation.

First-line / initial treatment: Hypothyroidism: levothyroxine PO. Myxedema coma: ICU, IV levothyroxine per protocol, stress-dose hydrocortisone until adrenal insufficiency excluded, supportive warming/ventilation, treat trigger.

Alternatives / escalation: Start lower and titrate slowly in older adults/CAD.

Monitoring / contraindications: TSH/free T4, symptoms, HR, angina, drug interactions (calcium/iron reduce absorption).

Clinical pearl: Take levothyroxine consistently apart from calcium/iron; over-replacement increases AF and bone loss risk.

Hyperthyroidism / Graves / thyroid storm

Pathophysiology: Excess thyroid hormone increases adrenergic tone and metabolism; causes weight loss, tremor, tachycardia, heat intolerance, diarrhea, anxiety. Storm is life-threatening fever, delirium, tachyarrhythmia, GI/hepatic dysfunction.

First-line / initial treatment: Symptom control with propranolol or other -blocker if tolerated. Antithyroid drugs: methimazole PO for many nonpregnant patients; propylthiouracil (PTU) in first trimester or thyroid storm protocols. Thyroid storm: PTU, iodine after thionamide, -blocker, corticosteroid, supportive ICU care.

Alternatives / escalation: Radioiodine or surgery in selected patients; cholestyramine sometimes adjunct in severe cases by specialist.

Monitoring / contraindications: TSH/free T4/T3, CBC for agranulocytosis symptoms, LFTs, HR/BP, pregnancy status.

Clinical pearl: Fever/sore throat on methimazole/PTU requires urgent evaluation for agranulocytosis.

Adrenal disorders / corticosteroid therapy

Pathophysiology: Adrenal insufficiency causes cortisol deficiency with fatigue, hypotension, hyponatremia, hyperkalemia; Cushing/exogenous steroids cause hyperglycemia, HTN, infection risk, osteoporosis, myopathy.

First-line / initial treatment: Adrenal crisis: hydrocortisone IV and fluids per emergency protocol. Chronic replacement: hydrocortisone/prednisone fludrocortisone depending on primary vs secondary. Anti-inflammatory steroid use: prednisone/methylprednisolone/dexamethasone with shortest effective duration.

Alternatives / escalation: Taper chronic steroids to avoid adrenal suppression; steroid-sparing agents in autoimmune disease when appropriate.

Monitoring / contraindications: BP, glucose, weight, infection, bone protection, mood, myopathy, adrenal crisis education.

Clinical pearl: Long-term steroids should not be abruptly stopped.

Bone metabolism: osteoporosis / vitamin D deficiency

Pathophysiology: Bone resorption exceeds formation, causing fragility fractures. Risk rises with aging, menopause, glucocorticoids, low vitamin D/calcium, immobility, endocrine disease.

First-line / initial treatment: Calcium/vitamin D adequacy, exercise/fall prevention. Bisphosphonates: alendronate PO weekly, risedronate PO, zoledronic acid IV for selected patients.

Alternatives / escalation: Denosumab SQ, teriparatide/abaloparatide in high-risk patients, estrogen/SERM in selected situations.

Monitoring / contraindications: DEXA, renal function, calcium/vitamin D, dental issues, esophagitis precautions.

Clinical pearl: Oral bisphosphonates require upright posture and water; avoid in significant esophageal disease.

Renal / Urologic / Fluid-Electrolyte

Acute kidney injury (prerenal, intrinsic, postrenal)

Pathophysiology: Prerenal: reduced perfusion; intrinsic: tubular/glomerular/interstitial injury; postrenal: obstruction. AKI impairs excretion of potassium, acid, water, and renally cleared drugs.

First-line / initial treatment: Treat cause: restore perfusion/volume if hypovolemic, stop nephrotoxins (NSAIDs, ACEI/ARB temporarily when appropriate, contrast, aminoglycosides), relieve obstruction, treat sepsis. Dose-adjust renally cleared medications.

Alternatives / escalation: Dialysis for refractory hyperkalemia, acidosis, volume overload, uremic complications, or toxins per nephrology.

Monitoring / contraindications: Creatinine/eGFR, urine output, K, bicarbonate, volume status, medication list.

Clinical pearl: Rising creatinine after starting ACEI/ARB can be expected mildly, but significant rise needs reassessment for renal artery stenosis, volume depletion, NSAIDs, or other causes.

Chronic kidney disease

Pathophysiology: Progressive nephron loss from diabetes, HTN, glomerulonephritis, interstitial disease, polycystic disease, or other causes. Leads to anemia, mineral-bone disorder, acidosis, hyperkalemia, uremia.

First-line / initial treatment: BP and diabetes control; ACEI/ARB for albuminuria when tolerated; SGLT2 inhibitor in selected diabetic/CKD patients per protocol; statin for CV risk; avoid nephrotoxins; dose-adjust drugs.

Alternatives / escalation: Diuretics for volume; bicarbonate for metabolic acidosis; erythropoiesis-stimulating agents/iron for selected anemia; phosphate binders/vitamin D analogs under nephrology.

Monitoring / contraindications: eGFR, albumin/creatinine ratio, K, bicarbonate, Ca/Phos/PTH, Hgb, BP, medication doses.

Clinical pearl: Metformin, DOACs, gabapentin/pregabalin, many antibiotics, digoxin, and colchicine require renal attention.

UTI: acute cystitis, pyelonephritis, complicated UTI

Pathophysiology: Ascending bacterial infection causes bladder inflammation; pyelo involves renal pelvis/parenchyma with fever/flank pain and systemic illness risk.

First-line / initial treatment: Uncomplicated cystitis: nitrofurantoin PO (avoid at term pregnancy and check renal limitations), TMP-SMX PO when appropriate, or fosfomycin PO. Pyelonephritis: oral ciprofloxacin/levofloxacin or TMP-SMX when susceptible; ceftriaxone IV or other IV therapy when severe, vomiting, pregnant, or resistant risk. Course materials list Bactrim, cefixime, ciprofloxacin, levofloxacin for pyelonephritis.

Alternatives / escalation: Pregnancy: avoid trimethoprim in pregnancy and avoid nitrofurantoin at term per course note; use pregnancy-safe options per protocol/culture.

Monitoring / contraindications: Symptoms, fever/flank pain, culture when complicated/pyelo/recurrent, renal function, QT/tendon/CNS risks with fluoroquinolones.

Clinical pearl: Do not treat asymptomatic bacteriuria except in specific situations such as pregnancy or before selected urologic procedures.

Nephrolithiasis / obstruction / BPH

Pathophysiology: Stones obstruct urine flow causing colicky flank pain, hematuria, hydronephrosis; BPH causes bladder outlet obstruction and LUTS.

First-line / initial treatment: Stone pain: NSAID such as ketorolac/ibuprofen if renal function and bleeding risk allow, antiemetic, hydration; tamsulosin for selected distal ureter stones. Infected obstructing stone: urgent urology + IV antibiotics. BPH: tamsulosin/alfuzosin; finasteride/dutasteride for enlarged prostate.

Alternatives / escalation: Procedural removal/lithotripsy for large/obstructing stones. BPH combination 1 blocker + 5-reductase inhibitor when indicated.

Monitoring / contraindications: Fever, creatinine, hydronephrosis, urine culture, post-void residual, PSA/prostate assessment as appropriate.

Clinical pearl: Fever + stone + obstruction is an emergency.

Overactive bladder / urge incontinence / neurogenic bladder

Pathophysiology: Detrusor overactivity or impaired neural control causes urgency, frequency, nocturia, urge incontinence. Rule out UTI, retention, medications, glucose, neurologic disease.

First-line / initial treatment: Bladder training, pelvic floor exercises. Medications: oxybutynin, tolterodine, solifenacin; 3 agonist mirabegron.

Alternatives / escalation: Topical estrogen for postmenopausal urogenital syndrome when appropriate; specialist options include botulinum toxin or neuromodulation.

Monitoring / contraindications: Anticholinergic effects, cognition/falls in older adults, constipation, urinary retention, BP with mirabegron.

Clinical pearl: Anticholinergic burden is a major geriatric safety issue.

Electrolyte/acid-base disorders

Pathophysiology: Kidneys and lungs maintain pH/electrolyte homeostasis. Hyperkalemia affects cardiac conduction; hyponatremia affects brain water balance; acidosis/alkalosis reflect metabolic or respiratory drivers.

First-line / initial treatment: Hyperkalemia with ECG changes: IV calcium gluconate, insulin + dextrose, albuterol, potassium removal strategies. Hyponatremia: treat based on symptoms/chronicity; severe symptomatic requires hypertonic saline protocol. Acidosis/alkalosis: treat underlying cause.

Alternatives / escalation: Loop diuretics, potassium binders, dialysis for refractory hyperkalemia/renal failure.

Monitoring / contraindications: ECG, serial electrolytes, glucose after insulin, neurologic status, fluid balance.

Clinical pearl: Correct sodium carefully to avoid osmotic demyelination.

Gastrointestinal / Hepatobiliary

GERD / esophagitis / Barrett risk

Pathophysiology: Lower esophageal sphincter dysfunction allows acid reflux, causing heartburn, regurgitation, chest/epigastric discomfort; chronic injury can cause strictures or Barrett esophagus.

First-line / initial treatment: Lifestyle: weight loss if indicated, avoid late meals/triggers, elevate head. Drug therapy: PPI such as omeprazole/pantoprazole PO for frequent or erosive symptoms; H2 blocker famotidine for milder/intermittent symptoms; antacids for rapid short relief.

Alternatives / escalation: Sucralfate in selected mucosal protection contexts; evaluate alarm symptoms or refractory disease.

Monitoring / contraindications: Alarm symptoms (dysphagia, bleeding, weight loss), long-term PPI need, Mg/B12/bone risk, renal concerns.

Clinical pearl: Chest/epigastric pain may require ECG/cardiac rule-out before assuming reflux.

Peptic ulcer disease / H. pylori

Pathophysiology: Mucosal defense injury from H. pylori, NSAIDs, acid, ischemia or stress leads to gastric/duodenal ulceration and bleeding/perforation risk.

First-line / initial treatment: Stop NSAID if possible. PPI such as omeprazole/pantoprazole. H. pylori regimen from course materials: amoxicillin + clarithromycin + PPI when appropriate; use alternative regimens if macrolide resistance/allergy risk per protocol.

Alternatives / escalation: Bismuth quadruple therapy often used in many protocols: PPI + bismuth + tetracycline + metronidazole; verify local protocol.

Monitoring / contraindications: GI bleeding, anemia, H. pylori eradication testing, NSAID/anticoagulant risk.

Clinical pearl: Do not miss malignancy/alarm symptoms in older patients or unexplained weight loss.

Nausea/vomiting including chemotherapy-induced

Pathophysiology: Emesis integrates GI tract, CTZ, vestibular, CNS and limbic inputs. Causes include infection, drugs, GI obstruction, metabolic disease, digoxin/theophylline toxicity, pregnancy, chemotherapy.

First-line / initial treatment: Non-chemo mild/moderate: phenothiazine prochlorperazine or promethazine; if inadequate, antihistamine/anticholinergic such as meclizine, dimenhydrinate, hydroxyzine, scopolamine. Chemo: ondansetron/granisetron/palonosetron, dexamethasone, NK1 antagonist per emetogenic risk; lorazepam for anticipatory nausea.

Alternatives / escalation: Metoclopramide for gastroparesis/diabetic gastric stasis; cannabinoids dronabinol/nabilone for refractory chemotherapy nausea per indication.

Monitoring / contraindications: Hydration, electrolytes, QT prolongation, sedation, extrapyramidal symptoms, bowel obstruction signs.

Clinical pearl: Persistent vomiting with obstruction signs requires diagnosis, not just antiemetics.

Constipation / opioid-induced constipation

Pathophysiology: Slow transit, outlet dysfunction, medications, dehydration, low fiber, immobility, metabolic disease, neurologic disease. Opioids reduce GI motility via micro receptors.

First-line / initial treatment: Fiber, fluids, activity when appropriate. Osmotic laxative polyethylene glycol; stimulant senna/bisacodyl; stool softener docusate has limited effect but often used. Opioid-induced: bowel regimen with stimulant osmotic at opioid start.

Alternatives / escalation: Lactulose, magnesium products if renal function safe; lubiprostone, linaclotide, plecanatide for selected chronic constipation/IBS-C; methylnaltrexone/naloxegol for refractory opioid-induced constipation.

Monitoring / contraindications: Red flags: bleeding, weight loss, anemia, obstruction, sudden change. Electrolytes with chronic laxative use.

Clinical pearl: Medication review is treatment: anticholinergics, opioids, iron, calcium, CCBs, diuretics, NSAIDs, antidepressants can contribute.

IBS / functional GI disorders

Pathophysiology: Disorder of gut-brain interaction with abdominal pain and altered bowel habits without structural explanation; stress, visceral sensitivity, motility changes, and psychosocial factors contribute.

First-line / initial treatment: Education, diet trigger management, soluble fiber for IBS-C, loperamide for diarrhea, PEG/linaclotide/lubiprostone for constipation pattern, antispasmodics such as dicyclomine/hyoscyamine for cramping.

Alternatives / escalation: Low-dose TCA for pain/diarrhea phenotype; SSRI in selected patients; CBT, gut-directed psychotherapy/hypnotherapy, stress management.

Monitoring / contraindications: Alarm signs, weight loss, bleeding, nocturnal symptoms, anemia, family history, response and quality of life.

Clinical pearl: IBS is real and impairing; treatment targets symptoms and gut-brain amplification.

IBD: ulcerative colitis and Crohn disease

Pathophysiology: Chronic immune-mediated intestinal inflammation. UC affects colon mucosa continuously; Crohn may affect any GI layer/segment and cause strictures/fistulas.

First-line / initial treatment: Mild UC: 5-ASA mesalamine PO/rectal. Flares: corticosteroids such as prednisone/budesonide. Maintenance/escalation: azathioprine/6-MP, methotrexate (Crohn), biologics such as infliximab/adalimumab/vedolizumab/ustekinumab per specialist.

Alternatives / escalation: Antibiotics for abscess/fistula complications; surgery for complications/refractory disease.

Monitoring / contraindications: CBC, LFTs, infection/TB/hepatitis screening before biologics, colon cancer surveillance, steroid complications.

Clinical pearl: Avoid chronic systemic steroid dependence; use steroid-sparing maintenance.

Acute diarrhea / C. difficile / diverticulitis

Pathophysiology: Diarrhea may be infectious, inflammatory, medication-related, malabsorptive. C. difficile follows antibiotic disruption of flora. Diverticulitis arises from inflamed/infected diverticula.

First-line / initial treatment: Hydration. C. difficile: oral vancomycin for severe/recurrent noted in course materials; metronidazole listed as treatment option. Diverticulitis course materials list Augmentin or cephalexin + metronidazole; severe cases need IV therapy/CT/surgery evaluation.

Alternatives / escalation: Avoid antimotility drugs in suspected invasive diarrhea or C. difficile unless directed.

Monitoring / contraindications: Fever, blood, dehydration, WBC, renal function, abdominal peritonitis signs.

Clinical pearl: Antibiotic exposure + watery diarrhea = think C. difficile.

Gallstones/cholecystitis, cirrhosis, GI bleed

Pathophysiology: Gallstones obstruct cystic/common bile duct causing biliary colic/cholecystitis/pancreatitis. Cirrhosis causes portal HTN, ascites, varices, coagulopathy, encephalopathy. GI bleeding causes anemia/shock risk.

First-line / initial treatment: Cholecystitis: NPO, fluids, analgesia, antibiotics per protocol, surgical evaluation. Cirrhosis ascites: sodium restriction, spironolactone furosemide. Encephalopathy: lactulose rifaximin. Variceal bleed: octreotide, antibiotics, endoscopy per protocol. Nonvariceal ulcer bleed: IV PPI and endoscopy.

Alternatives / escalation: Ursodiol in selected nonsurgical cholesterol stones; transplant referral for advanced cirrhosis.

Monitoring / contraindications: LFTs, bilirubin, INR, albumin, platelets, ammonia clinically, renal function, bleeding.

Clinical pearl: Cirrhosis changes drug metabolism and bleeding risk; avoid NSAIDs in many cirrhosis contexts.

Neurology / Psychiatry / Pain / Substance Use

Depression / major depressive disorder

Pathophysiology: Mood disorder involving monoamine neurotransmitter pathways, psychosocial/genetic factors, sleep/appetite/cognition changes, and suicide risk.

First-line / initial treatment: Psychotherapy plus first-line SSRI such as sertraline, fluoxetine, escitalopram, citalopram, paroxetine or SNRI such as venlafaxine/duloxetine. Course materials emphasize SSRIs/SNRIs first-line.

Alternatives / escalation: Bupropion, mirtazapine, trazodone, TCA (amitriptyline/nortriptyline), MAOI for later-line/specialist use; augment/switch when partial/nonresponse.

Monitoring / contraindications: Suicidality, serotonin syndrome, sexual effects, GI effects, QT, BP with SNRIs, hyponatremia in older adults, onset over weeks.

Clinical pearl: Energy may improve before mood/cognition; suicide monitoring is essential early in therapy.

Anxiety disorders / panic / GAD

Pathophysiology: Norepinephrine, serotonin, and GABA systems are implicated; chronic hyperarousal causes worry, panic symptoms, somatic complaints, avoidance.

First-line / initial treatment: CBT and SSRI/SNRI such as sertraline, escitalopram, venlafaxine, duloxetine. Buspirone for GAD. Short-term benzodiazepines (lorazepam, clonazepam, alprazolam) only when necessary and with caution.

Alternatives / escalation: Hydroxyzine PRN, pregabalin/gabapentin in selected contexts, propranolol for performance symptoms.

Monitoring / contraindications: Sedation/falls, dependence, respiratory depression with opioids/alcohol, activation, suicidality.

Clinical pearl: Benzodiazepines are not ideal first-line chronic therapy, especially in older adults.

Insomnia

Pathophysiology: Sleep initiation/maintenance disorder may be primary or due to pain, anxiety, depression, substances, sleep apnea, medications, poor sleep hygiene.

First-line / initial treatment: CBT-I and sleep hygiene. Short-term pharmacologic options: melatonin, doxepin low dose, zolpidem/eszopiclone/zaleplon, trazodone when comorbid depression/anxiety contexts.

Alternatives / escalation: Treat underlying OSA, restless legs, pain, depression. Avoid chronic sedative escalation.

Monitoring / contraindications: Falls, next-day impairment, complex sleep behaviors, anticholinergic burden, misuse.

Clinical pearl: In older adults, avoid benzodiazepines/sedative-hypnotics as first choice when possible.

ADHD

Pathophysiology: Neurodevelopmental disorder with deficits in attention, impulse control, executive function, emotional regulation; dopamine/norepinephrine pathways involved.

First-line / initial treatment: Stimulants: methylphenidate products or amphetamine products. Course materials list stimulants first-line.

Alternatives / escalation: Atomoxetine second-line/when stimulant contraindicated; guanfacine or clonidine; bupropion third-line in course materials.

Monitoring / contraindications: BP/HR, appetite/weight, sleep, misuse/diversion, anxiety/tics, cardiac history.

Clinical pearl: Use validated screening and assess childhood history/impairment, not symptoms alone.

Acute pain, chronic noncancer pain, neuropathic pain

Pathophysiology: Nociceptive pain follows tissue injury/inflammation; neuropathic pain follows abnormal nerve signaling; chronic pain involves peripheral/central sensitization.

First-line / initial treatment: Acute mild/moderate: acetaminophen, NSAIDs (ibuprofen, naproxen, ketorolac short term if appropriate), topical diclofenac/lidocaine. Neuropathic: gabapentin/pregabalin, duloxetine, amitriptyline/nortriptyline, topical lidocaine/capsaicin. Non-drug therapy and function goals.

Alternatives / escalation: Opioids such as morphine, hydromorphone, oxycodone, hydrocodone, fentanyl only for selected acute/severe/cancer/palliative contexts with risk assessment.

Monitoring / contraindications: Pain function score, sedation, constipation, respiratory depression, renal/GI/CV NSAID risk, misuse risk, PDMP.

Clinical pearl: Start bowel regimen when opioids are used; avoid opioid + benzodiazepine when possible.

Migraine

Pathophysiology: Neurovascular disorder involving trigeminal activation and CGRP-mediated vasodilation/inflammation; attacks may include nausea, photophobia, aura.

First-line / initial treatment: Acute: NSAID/acetaminophen for mild; triptans such as sumatriptan/rizatriptan for moderate-severe if no contraindication; antiemetic metoclopramide/prochlorperazine if nausea. Prevention: propranolol/metoprolol, topiramate, amitriptyline, CGRP monoclonals (erenumab, fremanezumab, galcanezumab) in selected patients.

Alternatives / escalation: Avoid triptans in significant CAD/uncontrolled HTN; consider gepants/ditans if in current protocol.

Monitoring / contraindications: Frequency, medication overuse, BP, pregnancy, neurologic red flags.

Clinical pearl: New worst headache, neuro deficit, fever/meningismus, or sudden thunderclap needs urgent evaluation.

Epilepsy / seizures

Pathophysiology: Abnormal synchronous neuronal firing causes focal or generalized seizures; triggers include structural lesions, metabolic derangements, withdrawal, infection, genetics.

First-line / initial treatment: Drug depends on seizure type: levetiracetam, lamotrigine, valproate, carbamazepine, phenytoin, topiramate, ethosuximide for absence seizures. Status epilepticus: benzodiazepine lorazepam IV then levetiracetam/fosphenytoin/valproate per protocol.

Alternatives / escalation: Avoid valproate in pregnancy when possible; CBD solution indicated in course source for Lennox-Gastaut/Dravet pediatric patients >=2 years.

Monitoring / contraindications: Seizure frequency, levels for selected drugs, CBC/LFT/Na, rash with lamotrigine, pregnancy/contraception interactions.

Clinical pearl: Match medication to seizure type; wrong antiseizure drug can worsen some seizure types.

Parkinson disease, Alzheimer disease, MS, ALS

Pathophysiology: PD: dopaminergic neuron loss. Alzheimer: cholinergic deficits and neurodegeneration. MS: immune demyelination. ALS: motor neuron degeneration.

First-line / initial treatment: PD: carbidopa/levodopa, dopamine agonists pramipexole/ropinirole, MAO-B selegiline/rasagiline, COMT entacapone, amantadine. Alzheimer: donepezil/rivastigmine/galantamine; memantine. MS: interferon beta, glatiramer, fingolimod, teriflunomide, dimethyl fumarate, natalizumab; symptoms with dalfampridine/baclofen. ALS: riluzole.

Alternatives / escalation: Specialist-guided disease-modifying therapy and rehab.

Monitoring / contraindications: Falls, cognition, hallucinations, bradycardia/GI effects with cholinesterase inhibitors, infection/liver/macular risks in MS drugs.

Clinical pearl: Treat symptoms, maintain function, and review anticholinergic burden in cognitive disorders.

Alcohol, opioid, tobacco, cannabis use disorders

Pathophysiology: Substance use disorders involve reward pathways, tolerance, withdrawal, craving, and impaired control. Genetics/family history and environment affect risk.

First-line / initial treatment: Alcohol: naltrexone, acamprosate, disulfiram in selected patients plus counseling/SBIRT. Opioid use disorder: buprenorphine, methadone, naltrexone plus naloxone rescue. Tobacco: nicotine replacement, varenicline, bupropion plus counseling. Cannabis: no FDA-approved medication; CBT/MET and symptom support.

Alternatives / escalation: Withdrawal management: benzodiazepines for alcohol withdrawal; clonidine/lofexidine adjuncts for opioid withdrawal symptoms; gabapentin sometimes used off-label in selected contexts.

Monitoring / contraindications: Withdrawal severity, overdose risk, LFTs, pregnancy, psychiatric comorbidity, adherence, relapse triggers.

Clinical pearl: SBIRT and motivational interviewing are clinical treatment tools, not just screening paperwork.

Hematology / Anticoagulation

Venous thromboembolism: DVT/PE

Pathophysiology: Clotting in venous system caused by stasis, endothelial injury, hypercoagulability; can embolize to lungs. Risk factors include surgery, trauma, immobility, estrogen therapy, malignancy, thrombophilia.

First-line / initial treatment: Anticoagulation: apixaban/rivaroxaban or LMWH/UFH bridge to warfarin depending on patient factors; heparin IV when rapid reversal/procedures/renal concerns; LMWH in some cancer/pregnancy contexts per protocol.

Alternatives / escalation: Thrombolysis/thrombectomy for massive PE or limb-threatening DVT in selected patients.

Monitoring / contraindications: Bleeding, renal function, CBC/platelets, INR if warfarin, duration based on provoked/unprovoked/recurrent risk.

Clinical pearl: Estrogen therapy is a reversible VTE risk factor from course materials.

Anticoagulant reversal and bleeding

Pathophysiology: Anticoagulants reduce clot formation but increase bleeding risk. Reversal depends on drug, timing, renal function, bleed severity.

First-line / initial treatment: Warfarin major bleeding: vitamin K + PCC per protocol. Heparin: protamine. Dabigatran: idarucizumab. Factor Xa inhibitors: andexanet alfa where available or PCC per protocol.

Alternatives / escalation: Hold drug, local control, transfusion/support, dialysis for dabigatran in selected cases.

Monitoring / contraindications: Hemodynamics, Hgb, platelets, renal function, INR/aPTT/anti-Xa where applicable, source control.

Clinical pearl: Do not reverse minor bleeding the same way as life-threatening bleeding; balance thrombosis risk.

Iron deficiency anemia, B12/folate deficiency, anemia of CKD

Pathophysiology: Iron deficiency impairs hemoglobin synthesis; B12/folate deficiency impairs DNA synthesis causing macrocytosis; CKD reduces erythropoietin.

First-line / initial treatment: Iron deficiency: oral ferrous sulfate/gluconate/fumarate; IV iron when malabsorption, intolerance, severe deficiency, CKD/dialysis contexts. B12: cyanocobalamin PO/IM; folate: folic acid PO. CKD anemia: iron repletion epoetin alfa/darbepoetin under protocol.

Alternatives / escalation: Investigate bleeding source, malabsorption, diet, heavy menses, GI malignancy risk.

Monitoring / contraindications: CBC, ferritin/TSAT, reticulocytes, B12/folate, stool/bleeding evaluation, ESA BP/thrombotic risk.

Clinical pearl: Treating anemia without identifying the cause can miss GI bleeding or malignancy.

Sickle cell disease

Pathophysiology: Sickled RBCs cause hemolytic anemia, vaso-occlusion, pain crises, acute chest syndrome, stroke risk, infection risk.

First-line / initial treatment: Pain crisis: hydration, oxygen if hypoxic, NSAID/opioid analgesia as needed, treat trigger. Disease-modifying: hydroxyurea; newer agents in uploaded drug watch include voxelotor and crizanlizumab for selected patients.

Alternatives / escalation: Transfusion/exchange transfusion for severe acute chest/stroke per specialist; penicillin prophylaxis/vaccines in children per protocol.

Monitoring / contraindications: CBC, reticulocytes, renal/liver, pain frequency, acute chest symptoms, infection fever.

Clinical pearl: Fever in sickle cell disease is urgent because functional asplenia increases severe infection risk.

Infectious Disease: Specific Diseases, Drugs, and Routes

Antimicrobial selection principles

Pathophysiology: Infection treatment requires site/source, likely pathogen, host factors, severity, cultures, susceptibility, penetration, allergy, renal/hepatic function, pregnancy, local resistance, and stewardship.

First-line / initial treatment: Start empiric therapy when needed, then narrow based on culture/clinical response. Convert IV to PO when improving, absorbing PO, and equivalent oral option exists.

Alternatives / escalation: Avoid antibiotics for viral URI/bronchitis unless bacterial diagnosis is likely.

Monitoring / contraindications: Clinical response 48-72h, cultures, WBC/fever, renal function, allergy, C. difficile, QT/tendon/CNS risks depending on drug.

Clinical pearl: Route: PO for stable outpatient infection; IV for sepsis, meningitis, severe pneumonia, severe SSTI, inability to take PO, immunocompromise, or need for high reliable levels.

Cellulitis / erysipelas / impetigo / purulent SSTI / abscess

Pathophysiology: Skin barrier disruption permits streptococci and/or Staphylococcus aureus infection. Cellulitis is diffuse erythema/warmth without pus; abscess is pus collection; purulence raises MRSA concern.

First-line / initial treatment: Nonpurulent mild cellulitis: cephalexin PO or dicloxacillin PO; severe/systemic: cefazolin IV or ceftriaxone IV; add MRSA coverage if risk/purulence. Purulent cellulitis/MRSA risk: doxycycline PO, TMP-SMX PO, or clindamycin PO; severe MRSA: vancomycin IV. Abscess: incision & drainage is primary; add antibiotics if systemic illness, extensive disease, immunocompromise, or high-risk features. Impetigo: mupirocin topical for limited; cephalexin PO/dicloxacillin PO for more extensive; MRSA options if suspected.

Alternatives / escalation: Diabetic foot: broader coverage based on severity; course materials list cephalexin, Bactrim, doxycycline for skin/soft tissue categories; severe diabetic foot often needs IV broad-spectrum and imaging for osteomyelitis.

Monitoring / contraindications: Borders, fever, pain out of proportion, drainage, culture if purulent/severe, renal function, allergy, C. difficile risk.

Clinical pearl: Doxycycline is usually PO for outpatient MRSA-risk SSTI; IV therapy is for severe/systemic/hospital cases and often uses vancomycin rather than doxycycline.

Necrotizing fasciitis

Pathophysiology: Rapid deep fascial infection with toxin-mediated tissue necrosis, severe pain, systemic toxicity, shock risk.

First-line / initial treatment: Emergency surgery + broad IV antibiotics: vancomycin IV plus piperacillin-tazobactam IV or carbapenem; add clindamycin IV for toxin suppression when streptococcal/clostridial concern per protocol.

Alternatives / escalation: ICU resuscitation, repeated debridement, cultures, organ support.

Monitoring / contraindications: Pain out of proportion, crepitus, bullae, hypotension, lactate, renal function, CK, surgical findings.

Clinical pearl: Do not wait for imaging if clinical suspicion is high.

Meningitis

Pathophysiology: Infection/inflammation of meninges causes fever, headache, neck stiffness, altered mental status, seizures; rapid progression can be fatal.

First-line / initial treatment: Course materials note hospital regimen vancomycin IV + ceftriaxone IV. Adult empiric often includes vancomycin IV plus ceftriaxone/cefotaxime IV; add ampicillin IV for Listeria risk (older adults, pregnancy, immunocompromised) per protocol. Dexamethasone may be used early in selected bacterial meningitis protocols.

Alternatives / escalation: Tailor to organism and susceptibilities; antiviral acyclovir IV if HSV encephalitis concern.

Monitoring / contraindications: Neurologic status, cultures, renal function, drug levels for vancomycin, hearing complications.

Clinical pearl: This is IV emergency therapy; oral antibiotics are not appropriate initial meningitis treatment.

Respiratory bacterial infections: CAP, COPD exacerbation, sinusitis, AOM, strep throat

Pathophysiology: See respiratory section; antibiotic choice depends on likely pathogen and severity.

First-line / initial treatment: CAP outpatient: amoxicillin PO or doxycycline PO from course materials. COPD exacerbation with bacterial features: amoxicillin-clavulanate PO, doxycycline PO, or azithromycin PO depending on risk/protocol. Sinusitis/AOM: amoxicillin PO or amoxicillin-clavulanate PO. Strep throat: penicillin V PO, amoxicillin PO, or benzathine penicillin G IM.

Alternatives / escalation: Severe CAP/hospital: ceftriaxone IV + azithromycin IV/PO or respiratory fluoroquinolone per protocol.

Monitoring / contraindications: O2, fever, sputum, QT, renal, allergies.

Clinical pearl: Doxycycline is PO for many outpatient respiratory infections; IV route is generally reserved for hospitalized/severe disease with appropriate IV regimens.

UTI / pyelonephritis

Pathophysiology: Ascending urinary pathogens cause cystitis; pyelo causes renal infection with fever/flank pain and bacteremia risk.

First-line / initial treatment: Uncomplicated cystitis: nitrofurantoin PO, TMP-SMX PO, fosfomycin PO. Pyelonephritis: ciprofloxacin/levofloxacin PO if stable and susceptible; ceftriaxone IV initial or inpatient IV therapy for severe/vomiting/systemic illness. Course materials list Bactrim, cefixime, ciprofloxacin, levofloxacin for acute pyelonephritis.

Alternatives / escalation: Pregnancy/complicated cases need culture-guided and pregnancy-safe regimens.

Monitoring / contraindications: Urine culture, fever, flank pain, renal function, pregnancy, resistance.

Clinical pearl: Nitrofurantoin treats bladder infection but is not used for pyelonephritis because tissue levels are inadequate.

STIs: chlamydia, gonorrhea, trichomoniasis, bacterial vaginosis, syphilis

Pathophysiology: STIs may be asymptomatic and cause PID, infertility, ectopic pregnancy, neonatal infection, disseminated infection.

First-line / initial treatment: Course materials list chlamydia: doxycycline or azithromycin; gonorrhea: ceftriaxone (and ciprofloxacin in older course list, but verify current local guidance); trichomoniasis/BV: metronidazole. Syphilis: penicillin is treatment of choice in antimicrobial slide content.

Alternatives / escalation: Treat partners, test for coinfections, pregnancy-specific regimens, abstain until treatment complete.

Monitoring / contraindications: NAAT/culture when indicated, pregnancy, HIV/syphilis/hepatitis testing, retesting for reinfection.

Clinical pearl: Ceftriaxone IM is typical route for gonorrhea in modern practice; verify current CDC/local guidance before use.

C. difficile, H. pylori, diverticulitis

Pathophysiology: C. difficile follows antibiotic-associated dysbiosis; H. pylori causes chronic gastritis/ulcer risk; diverticulitis is inflamed/infected diverticula.

First-line / initial treatment: C. difficile: oral vancomycin for severe/recurrent noted in course; metronidazole also listed. H. pylori: amoxicillin + clarithromycin + PPI in course materials when appropriate. Diverticulitis: Augmentin or cephalexin + metronidazole listed in course materials; severe disease may need IV regimens.

Alternatives / escalation: Adjust for allergy, resistance, severity, local protocol.

Monitoring / contraindications: Diarrhea frequency, dehydration, WBC/renal, abdominal peritonitis, eradication test for H. pylori.

Clinical pearl: Oral vancomycin is used for gut lumen C. difficile; IV vancomycin does not treat colonic lumen disease adequately.

Fungal infections: tinea, candidiasis, systemic fungal disease

Pathophysiology: Dermatophytes infect keratinized tissue; Candida overgrows in moist areas or immunocompromise; systemic fungal infections require targeted therapy.

First-line / initial treatment: Tinea corporis/pedis: topical terbinafine or clotrimazole. Tinea capitis/nails or extensive disease: oral terbinafine or griseofulvin depending on site. Candidal diaper/intertrigo: nystatin topical or azole topical. Severe/systemic: fluconazole, amphotericin B, echinocandins per organism/site.

Alternatives / escalation: Check interactions for azoles; liver monitoring for systemic antifungals.

Monitoring / contraindications: LFTs for oral azoles/terbinafine, drug interactions, immunosuppression, treatment duration.

Clinical pearl: Tinea capitis generally needs systemic therapy; topical alone is inadequate.

Antivirals: influenza, HSV/VZV, HIV, hepatitis overview

Pathophysiology: Viruses require replication-cycle targeting. Antivirals are most effective early and in high-risk patients.

First-line / initial treatment: Influenza: oseltamivir PO early/high-risk. HSV/VZV: acyclovir/valacyclovir/famciclovir. HIV: combination ART using multiple classes; PrEP: tenofovir/emtricitabine for high-risk HIV-negative patients per uploaded PrEP article. Hepatitis antivirals are specialist-guided.

Alternatives / escalation: Severe HSV encephalitis: acyclovir IV.

Monitoring / contraindications: Renal function for acyclovir/tenofovir, adherence, resistance, HIV testing before PrEP, hepatitis labs.

Clinical pearl: Do not start PrEP without confirming HIV-negative status and renal appropriateness.

Dermatology / Allergy / Eye

Contact dermatitis / atopic dermatitis

Pathophysiology: Atopic dermatitis involves barrier dysfunction and immune dysregulation; contact dermatitis may be irritant or type IV delayed hypersensitivity (poison ivy example in course). Itch leads to excoriation and secondary infection risk.

First-line / initial treatment: Avoid trigger, emollients, topical corticosteroids: hydrocortisone low potency for face/folds, triamcinolone/mometasone for stronger body use when appropriate. Oral antihistamines cetirizine/loratadine/diphenhydramine for itch/sleep. Severe widespread allergic contact dermatitis: oral prednisone taper/burst as course notes allow.

Alternatives / escalation: Tacrolimus/pimecrolimus for sensitive areas/long-term steroid sparing; antibiotics only if secondary infection.

Monitoring / contraindications: Skin thinning, infection, trigger exposure, sleep/itch severity.

Clinical pearl: Topical steroid potency must match site and duration; face/groin require lower potency.

Psoriasis / psoriatic arthritis

Pathophysiology: Immune-mediated TNF-, IL-23, IL-17 inflammation causes keratinocyte proliferation, plaques, nail changes, and arthritis risk.

First-line / initial treatment: Mild/local: topical corticosteroids, calcipotriene, tazarotene, coal tar/salicylic acid; scalp preparations. Moderate/severe or psoriatic arthritis: phototherapy, methotrexate, cyclosporine, acitretin, biologics (adalimumab, infliximab, etanercept, ustekinumab, secukinumab) under specialist.

Alternatives / escalation: Screen for TB/hepatitis before biologics; manage CV/metabolic risk.

Monitoring / contraindications: BSA/PASI or functional impact, joints/nails, CBC/LFT/renal depending on drug, infection risk.

Clinical pearl: Erythrodermic or pustular psoriasis can be unstable and may require hospitalization.

Acne / rosacea

Pathophysiology: Acne involves follicular plugging, sebum, Cutibacterium acnes, inflammation. Rosacea involves facial vascular/inflammatory dysregulation with erythema, flushing, papules/pustules.

First-line / initial treatment: Acne: benzoyl peroxide, topical retinoid adapalene/tretinoin, topical clindamycin with benzoyl peroxide; moderate inflammatory acne: doxycycline/minocycline PO; severe nodular: isotretinoin specialist. Rosacea: metronidazole topical, azelaic acid, ivermectin; oxymetazoline for persistent erythema.

Alternatives / escalation: Hormonal acne: combined OCPs/spironolactone in selected patients.

Monitoring / contraindications: Pregnancy prevention with retinoids/isotretinoin, photosensitivity with doxycycline, GI upset, mood, liver/lipids with isotretinoin.

Clinical pearl: Avoid antibiotic monotherapy for acne; combine with benzoyl peroxide to reduce resistance.

Allergic rhinitis, urticaria, anaphylaxis

Pathophysiology: Type I IgE-mediated mast cell activation causes histamine symptoms. Anaphylaxis causes airway, breathing, circulation, skin/GI involvement.

First-line / initial treatment: Rhinitis: intranasal corticosteroid fluticasone/mometasone, oral antihistamines cetirizine/loratadine/fexofenadine, azelastine nasal. Urticaria: second-generation antihistamine. Anaphylaxis: epinephrine IM first-line immediately, airway/oxygen/IV fluids, repeat epinephrine as needed.

Alternatives / escalation: Montelukast adjunct in selected allergic rhinitis/asthma; immunotherapy for selected allergies; steroids/antihistamines are adjuncts after epinephrine in anaphylaxis.

Monitoring / contraindications: Airway, biphasic reaction, trigger identification, epinephrine autoinjector education.

Clinical pearl: Antihistamines do not replace epinephrine for anaphylaxis.

Red eye emergencies / conjunctivitis / blepharitis

Pathophysiology: Benign conjunctivitis must be separated from AACG, keratitis, uveitis, scleritis, orbital cellulitis, globe rupture. Pain, photophobia, vision loss, halos, proptosis, contact lens use, trauma are red flags.

First-line / initial treatment: Conjunctivitis/blepharitis: Polytrim drops listed in antibiotic infographic; contact lens bacterial concern: ofloxacin ophthalmic listed for contact lens wearers. AACG: acetazolamide, timolol, pilocarpine per emergency ophthalmology. Globe rupture: shield, IV antibiotics, urgent ophthalmology. Orbital cellulitis: IV vancomycin + ceftriaxone/ampicillin-sulbactam type therapy per protocol.

Alternatives / escalation: Avoid steroids in undiagnosed red eye unless ophthalmology directs.

Monitoring / contraindications: Visual acuity, pupils, fluorescein, IOP if trained, EOM pain/proptosis, fever.

Clinical pearl: Contact lens wearer with painful red eye = treat as possible keratitis and urgent evaluation.

Musculoskeletal / Autoimmune / Oncology / Special Populations

Osteoarthritis

Pathophysiology: Degenerative joint disease with cartilage loss, osteophytes, subchondral bone remodeling, pain, stiffness <30 min, crepitus, functional limitation.

First-line / initial treatment: Exercise/PT, weight loss, topical diclofenac for knee/hand, acetaminophen as option, oral NSAIDs (ibuprofen/naproxen/celecoxib) when benefits outweigh GI/CV/renal risk.

Alternatives / escalation: Intra-articular corticosteroid injections; duloxetine for chronic OA pain in selected patients; orthopedic referral when severe.

Monitoring / contraindications: Pain/function, BP, renal function, GI bleeding, edema, anticoagulants.

Clinical pearl: Topical NSAIDs reduce systemic exposure and are favored in many older/high-risk patients.

Gout / hyperuricemia

Pathophysiology: Monosodium urate crystals trigger intense neutrophilic inflammation, often first MTP, ankle, knee. Chronic hyperuricemia causes tophi and renal stones.

First-line / initial treatment: Acute flare: NSAID, colchicine, or corticosteroid depending on renal/GI/CV risks. Chronic urate lowering: allopurinol first common option; febuxostat alternative in selected patients; prophylaxis with low-dose colchicine/NSAID during initiation.

Alternatives / escalation: Avoid starting/stopping urate-lowering abruptly during flare unless already taking; adjust allopurinol in CKD.

Monitoring / contraindications: Serum urate target, renal function, rash, CBC/LFT if needed, flare frequency.

Clinical pearl: Treat acute inflammation first; long-term cure requires urate lowering when indicated.

Rheumatoid arthritis / autoimmune inflammatory disease

Pathophysiology: Autoimmune synovitis causes joint inflammation, erosions, deformity; systemic inflammation increases CV and organ risk.

First-line / initial treatment: Early DMARD therapy: methotrexate anchor drug with folic acid; hydroxychloroquine or sulfasalazine in selected milder disease; NSAIDs/steroids only bridge symptoms.

Alternatives / escalation: Biologics/targeted DMARDs: TNF inhibitors adalimumab/etanercept/infliximab, abatacept, rituximab, tocilizumab, JAK inhibitors under specialist.

Monitoring / contraindications: CBC, LFTs, renal, pregnancy, infection/TB/hepatitis screening, eye exams for hydroxychloroquine.

Clinical pearl: Steroids relieve symptoms but do not replace DMARD disease control.

Drug-induced myopathy

Pathophysiology: Muscle toxicity can result from statins, fibrates, glucocorticoids, colchicine, hydroxychloroquine/chloroquine, amiodarone, zidovudine and others; may cause myalgia, weakness, CK elevation, rhabdomyolysis.

First-line / initial treatment: Assess medication history and timing; stop or reduce offending drug when clinically appropriate; check CK/renal function/urinalysis if severe.

Alternatives / escalation: Switch statin, reduce dose, use hydrophilic statin or nonstatin lipid agent when needed; manage rhabdomyolysis with urgent fluids/support.

Monitoring / contraindications: Muscle pain/weakness, CK, creatinine, urine color, interacting drugs such as macrolides/azoles.

Clinical pearl: Statin + fibrate or statin + CYP inhibitor increases myopathy risk.

Cancer pharmacology overview

Pathophysiology: Cancer drugs target DNA replication, mitosis, hormones, growth signaling, immune checkpoints, or malignant immune cells. Toxicity occurs in rapidly dividing normal tissues and organ-specific targets.

First-line / initial treatment: Examples by class: cyclophosphamide (alkylator), cisplatin (platinum), methotrexate/5-FU (antimetabolites), doxorubicin (anthracycline), paclitaxel (taxane), vincristine (vinca), tamoxifen/anastrozole (hormonal), imatinib (targeted), rituximab/trastuzumab (monoclonal antibodies), checkpoint inhibitors.

Alternatives / escalation: Supportive meds: ondansetron/palonosetron, dexamethasone, NK1 antagonist; growth factors; antimicrobial prophylaxis in selected regimens.

Monitoring / contraindications: CBC/neutropenia, infection, nausea, renal/hepatic function, neuropathy, cardiomyopathy (anthracyclines/trastuzumab), extravasation, fertility/pregnancy.

Clinical pearl: Chemotherapy prescribing is specialist/protocol-based; Module 15 is for mechanism and safety recognition.

Pregnancy/lactation, pediatrics, geriatrics

Pathophysiology: Physiology changes drug absorption, distribution, metabolism and elimination. Neonates have immature renal/hepatic function; pregnancy changes volume and placental transfer; older adults have reduced renal reserve, polypharmacy, falls/cognition risks.

First-line / initial treatment: Use age/pregnancy/lactation-specific references. Pediatrics: weight-based dosing; BSA for some oncology/critical drugs. Pregnancy: avoid teratogens and choose safer alternatives. Geriatrics: start low/go slow, deprescribe when possible, use Beers principles.

Alternatives / escalation: Nonpharmacologic therapy when safer and effective; consult pharmacy/specialist for high-risk drugs.

Monitoring / contraindications: Growth/development, fetal/infant risk, renal/hepatic function, sedation/falls, anticholinergic burden.

Clinical pearl: A drug safe in adults may be unsafe in pregnancy, neonates, or older adults.